We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+10.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.08B
AUM Growth
+$170M
Cap. Flow
-$43.5M
Cap. Flow %
-1.41%
Top 10 Hldgs %
31.64%
Holding
198
New
2
Increased
42
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$41.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$21.9M
3
UTHR icon
United Therapeutics
UTHR
+$14.5M
4
TMO icon
Thermo Fisher Scientific
TMO
+$12.5M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.5M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$21.8M
2
STE icon
Steris
STE
+$20M
3
ILMN icon
Illumina
ILMN
+$18.6M
4
WAT icon
Waters Corp
WAT
+$17.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.67%
2 Real Estate 2.94%
3 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
51
BeOne Medicines Ltd
ONC
$33.4B
$15.8M 0.51%
45,983
+5,594
+14% +$1.85M
SRPT icon
52
Sarepta Therapeutics
SRPT
$1.64B
$15M 0.49%
193,224
+64,237
+50% +$4.87M
ADPT icon
53
Adaptive Biotechnologies
ADPT
$3.87B
$13.8M 0.45%
337,722
– –
IQV icon
54
IQVIA
IQV
$39.1B
$13.8M 0.45%
56,766
-13,100
-19% -$3.02M
GTHX
55
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$13.7M 0.45%
624,369
+232,615
+59% +$5.17M
NBP
56
NovaBridge Biosciences American Depositary Shares
NBP
$190M
$13.6M 0.44%
162,580
-4,316
-3% -$285K
MTD icon
57
Mettler-Toledo International
MTD
$27.9B
$13.6M 0.44%
9,800
– –
MRTX
58
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$13.5M 0.44%
83,784
– –
ARNA
59
DELISTED
Arena Pharmaceuticals Inc
ARNA
$13.4M 0.44%
196,385
– –
IONS icon
60
Ionis Pharmaceuticals
IONS
$8.81B
$12.9M 0.42%
322,521
+106,150
+49% +$4.16M
RARE icon
61
Ultragenyx Pharmaceutical
RARE
$2.56B
$12.8M 0.42%
134,590
+37,110
+38% +$3.87M
BNTX icon
62
BioNTech
BNTX
$23.5B
$12.8M 0.42%
57,073
-11,741
-17% -$2.21M
NVS icon
63
Novartis
NVS
$301B
$12.4M 0.4%
136,225
– –
CVS icon
64
CVS Health
CVS
$134B
$12.3M 0.4%
147,453
-72,542
-33% -$5.94M
IOVA icon
65
Iovance Biotherapeutics
IOVA
$2.09B
$12.2M 0.4%
468,538
-52,057
-10% -$1.35M
JAZZ icon
66
Jazz Pharmaceuticals
JAZZ
$16.2B
$12M 0.39%
67,456
– –
VTR icon
67
Ventas
VTR
$44.7B
$11.9M 0.39%
208,108
– –
ALXN
68
DELISTED
Alexion Pharmaceuticals
ALXN
$11.8M 0.38%
64,453
-46,240
-42% -$7.94M
AMED
69
DELISTED
Amedisys
AMED
$11.8M 0.38%
48,070
+28,675
+148% +$7.52M
DNLI icon
70
Denali Therapeutics
DNLI
$3.86B
$11.8M 0.38%
150,086
– –
BBIO icon
71
BridgeBio Pharma
BBIO
$16.1B
$11.5M 0.37%
188,767
+114,053
+153% +$6.51M
KRTX
72
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$11.5M 0.37%
100,458
+15,222
+18% +$1.78M
ALLK
73
DELISTED
Allakos
ALLK
$11.4M 0.37%
133,045
-30,600
-19% -$3.06M
DCPH
74
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$11.3M 0.37%
307,703
– –
ACH
75
Accendra Health
ACH
$256M
$11.3M 0.37%
266,023
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Tekla Capital Management held 198 positions worth $3.08B, up 5.9% from $2.91B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Tekla Capital Management's Q2 2021 filing shows 2 new, 42 increased, 41 reduced and 9 closed positions. Its largest new stake was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M. The largest sale was Elevance Health, an estimated $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q2 2021 buy was VectivBio Holding AG Ordinary Shares: 145,000 shares worth $1.69M.
  • Tekla Capital Management added most to UnitedHealth in Q2 2021, an estimated $41.2M increase.
  • Tekla Capital Management's biggest Q2 2021 reduction was Elevance Health, cutting an estimated $21.8M.
  • Tekla Capital Management fully exited Morphic Holding, Inc. Common Stock in Q2 2021, selling an estimated $5.67M.
  • Tekla Capital Management's ten largest holdings make up 32% of its $3.08B portfolio in Q2 2021.
  • Tekla Capital Management opened 2 new positions and closed 9 in Q2 2021.
  • Tekla Capital Management's portfolio value rose 5.9% quarter-over-quarter to $3.08B.

Based on Tekla Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.